Parexel, one of the largest contract research organizations supporting regulated clinical trials, will take the stage across eight sessions at the 2026 Drug Information Association (DIA) Global Annual Meeting, signaling continued industry investment in AI-enabled trial infrastructure, real-world evidence (RWE), and risk-based quality management. While the event skews toward pharmaceutical and biotech audiences, the methodological frameworks on display carry direct implications for functional food and dietary supplement brands seeking defensible clinical substantiation for structure-function claims.
The four-day conference agenda includes presentations, panels, and moderated discussions spanning AI applications across the full clinical trial lifecycle — from protocol design and patient recruitment through data collection and regulatory submission. Risk-based quality management (RBQM) and patient-centered research round out the thematic tracks. For supplement brands navigating the increasingly evidence-hungry retail and practitioner channels, these aren't abstract concepts: double-blind, placebo-controlled study designs validated through RBQM frameworks are increasingly the baseline expectation for premium finished formulation positioning.
The convergence of AI and RWE in trial design is particularly relevant to the nutraceutical sector, where smaller study budgets have historically limited access to the kind of peer-reviewed, clinical-endpoint data that commands shelf placement at major specialty and natural retailers. AI-assisted site selection, adaptive trial designs, and RWE integration can meaningfully compress both timelines and per-subject costs — lowering the barrier for ingredient suppliers and branded stack developers to generate bioavailability data, dose-response curves, and population-specific efficacy signals.
The functional food and supplement category has seen mounting pressure from the FTC and FDA to move beyond anecdotal structure-function claims toward reproducible, statistically significant outcomes. Brands that arrive at retail with peer-reviewed data — particularly from trials designed under current RBQM standards — are better positioned to defend label language and negotiate co-manufacturing or white-label partnerships with quality-focused retailers. Parexel's visibility at DIA 2026 underscores that the CRO infrastructure to support that kind of work is maturing rapidly, even for non-pharmaceutical sponsors.
The 2026 DIA Global Annual Meeting runs four days and draws regulatory professionals, clinical operations leaders, and drug and device developers from across the globe. Functional food operators and ingredient suppliers with active or planned clinical programs may find the AI and RWE sessions particularly actionable as they scope study designs for condition-specific health claims or look to validate novel bioactive ingredient pipelines ahead of NDI notifications or GRAS self-affirmation submissions.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.